Our Heritage
CoraLuma’s foundation is deeply rooted in the visionary work of David Purdy, who first conceptualized the continuous spectroscopic detection of glucose. To pursue this ambition, Purdy assembled a formidable group of talented scientists and engineers—including Dr. Ralf Marbach who contributed his foundational work, Michael Pitsakis, and Jeremy Grata—whose early non-invasive spectrophotometry efforts proved the foundational physics of the field.
While those initial optical diagnostic systems successfully demonstrated critical physical principles, they were ultimately constrained by the era’s limitations in computational calibration and hardware miniaturization. Today, CoraLuma honors David Purdy’s original vision by reuniting this core leadership team. We are building upon our shared historical insights, leveraging modern advanced chemometrics and precision opto-mechanics to finally solve the calibration bottlenecks of the past and bring his concept to clinical reality.
Leadership & Advisors
Jeremy Grata — Founder & CEO
Optical engineering and R&D leader with more than 30 years of experience in system integration, metrology, and product development. Profile: linkedin.com/in/jeremy-grata-5791546
Michael Pitsakis — Founder & CTO
Engineering executive with extensive experience in Class II/III medical devices, optical physics, DSP‑based biosignal extraction, and regulatory compliance. Profile: linkedin.com/in/mikepitsakis
Dr. Ralf Marbach — Senior Scientific Advisor
Expert in applied spectroscopy, biological covariance modeling, and statistical background projection. Profile: linkedin.com/in/ralf-marbach
Dr. Robert Norwood — Photonics Advisor
Dr. Robert A. Norwood — Optica, SPIE and National Academy of Inventors Fellow. Profile: linkedin.com/in/robert-norwood-5862111
Sven Schönfelder — Manufacturing Advisor
General Manager, Insion GmbH — a leading premier manufacturer of monolithic micro-spectrometers. His contribution potential anchors CoraLuma’s commercial production scaling and supply chain integrity for high-fidelity optical components. Email: Sven.Schoenfelder@insion.de
Patents & Literature
- US Provisional Patent Application No. 64/171,886 — System and Processing Pipeline for Universal Calibration and Extraction of Spectroscopic Biomarkers (Patent Pending).
- US Provisional Patent Application No. 64/141,239 — System and Processing Pipeline for Universal Calibration and Extraction of Spectroscopic Biomarkers (Patent Pending).
- US Patent 9,037,206 (2015) — Non‑Invasive Sensing of Glucose.
- US Patent 8,140,139 (2012) — Non‑Invasive Sensing of Glucose.
Representative publications in the broader field of optical spectroscopy and non‑invasive sensing:
- Marbach, Journal of Biomedical Optics, 2002
- Tarumi et al., Physics in Medicine & Biology, 2003
- Yamakoshi et al., Journal of Biomedical Optics, 2006
- Heise et al., Biosensors, 2021
- Li et al., Biomedical Signal Processing and Control, 2025
Contact CoraLuma
Jeremy Grata, CEO: grata@coraluma.com
Michael Pitsakis, CTO: mike@coraluma.com
Forward‑Looking Statement
This website contains forward‑looking statements regarding CoraLuma’s research, development plans, regulatory strategy, and potential market applications. These statements are based on current expectations and are subject to risks, uncertainties, and changes in assumptions. Actual results, performance, regulatory outcomes, and timelines may differ materially. Nothing herein constitutes an offer to sell or a solicitation of an offer to buy any securities. Any securities offering will be made solely to verified accredited investors in compliance with SEC Regulation D.
FDA Investigational Device Notice
Caution: Investigational Device. Limited by Federal law to investigational use. Not available for sale in the United States.